AstraZeneca's AZD0780 has demonstrated significant efficacy in a Phase IIb trial, showing a 50.7% reduction in LDL-C after 12 weeks when added to standard statin therapy. The treatment helped 84% of ...

New data from the PURSUIT Phase IIb trial reveal AstraZeneca‘s investigational oral PCSK9 inhibitor, AZD0780, delivers ...

AstraZeneca’s AZD0780 is an investigational oral medication that was developed to lower low-density lipoprotein cholesterol ...

Positive results from the PURSUIT Phase IIb trial of AstraZeneca’s AZD0780 have shown a statistically significant low-density lipoprotein cholesterol (LDL-C) reduction when administered on top of ...

AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol reduction when administered on top of standard-of-care statin therapy, as compared with placebo. AZD0780 is an ...

An investigational PCSK9 inhibitor with a different mechanism from existing drugs in this class has been shown to safely and effectively lower cholesterol levels.

AstraZeneca has revealed phase 2b results with its oral PCSK9 inhibitor AZD0780, including a more than 50% reduction in ...

In a phase 2b study, treatment with a once-daily oral PCSK9 inhibitor added to statin therapy resulted in a more than 50% ...

Positive results from the PURSUIT phase IIb trial for AstraZeneca’s AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol (LDL-C) reduction when administered on top of ...

Results from the PURSUIT Phase IIb trial for AstraZeneca’s (AZN) AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol reduction when administered on top of ...